Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07546695
What this trial is testing

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Who this might be right for
Breast Cancer
University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Testing effectiveness (Phase 2)Study completedNCT01855828
What this trial is testing

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Who this might be right for
Her2-Positive Breast Cancer
Yale University 50
Early research (Phase 1)Not Yet RecruitingNCT07601620
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 258
Not applicableUnknownNCT06015100
What this trial is testing

Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis

Who this might be right for
Breast Cancer
Yan Xue 40
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT04829604
What this trial is testing

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Ambrx, Inc. 72
Not applicableLooking for participantsNCT05314114
What this trial is testing

Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Who this might be right for
Breast Cancer Female
Peking University 136
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Not applicableStudy completedNCT01081600
What this trial is testing

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Who this might be right for
Breast Cancer
University Medical Center Groningen 7
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Early research (Phase 1)WithdrawnNCT06341647
What this trial is testing

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
GC Cell Corporation
Very early researchActive Not RecruitingNCT05333874
What this trial is testing

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Who this might be right for
Breast Cancer, Early-Onset
Rutgers, The State University of New Jersey 34
Testing effectiveness (Phase 2)Looking for participantsNCT07220135
What this trial is testing

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 100
Not applicableStudy completedNCT01615068
What this trial is testing

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Who this might be right for
Breast Cancer
Genentech, Inc. 1,007
Testing effectiveness (Phase 2)Looking for participantsNCT07285382
What this trial is testing

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo 120
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Large-scale testing (Phase 3)UnknownNCT03085368
What this trial is testing

Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Who this might be right for
HER2-positive Breast Cancer
Peking Union Medical College Hospital 482
Next Page